Prophylactic Human Vaccine Market Size, Share, Outlook, and Opportunity Analysis, 2022-2028
Prophylactic Human Vaccine Market
Prophylactic human vaccinations
boost the immune response and are intended to decrease the impact of potential
pathogen-caused diseases in humans. Novel vaccine production technologies are
being used to generate Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV)
vaccines. The Human Papillomavirus is a family of over 200 viruses, more than
40 of which are transmitted by direct sexual contact. Several HPV viruses have
been linked to cervical, anal, oropharyngeal, penile, vulvar, and vaginal
cancers.
During the projected period, the prophylactic
human vaccine market is
expected to grow due to an increase in pipeline research and increased
involvement of key players in vaccine development. CureVac AG, for example,
announced in October 2018 that it would begin a dose escalation phase I
clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a preventive
vaccine that contains the rabies virus glycoprotein RABV-G. This allows
vaccinated individuals' own cells to manufacture RABV-G protein, triggering an
immunological response. The investigation is expected to be completed in
January 2021.
Furthermore, in October 2018,
Valneva SE reported success in its Phase 1 programme aimed at developing a
single-dose vaccine against Chikungunya. It is intended for single-dose
preventive immunisation against Chikungunya in humans. The vaccine is designed
to provide long-lasting protection with a safety profile similar to other
authorised vaccines for active vaccination in adults and children.
Comments
Post a Comment